Neoantigen and tumor antigen-specific immunity transferred from immunized donors is detectable early after allogeneic transplantation in myeloma patients

作者：Foglietta M; Neelapu S S; Kwak L W^*; Jiang Y; Nattamai D; Lee S T; Fowler D H; Sportes C; Gress R E; Steinberg S M; Vence L M; Radvanyi L; Dwyer K C; Qazilbash M H; Bryant R N K; Bishop M R

来源：Bone Marrow Transplantation, 2013, 48(2): 269-277.

DOI：10.1038/bmt.2012.132

• myeloma
• allogeneic
• donor vaccination
• idiotype

To enhance the therapeutic index of allogeneic hematopoietic SCT (HSCT), we immunized 10 HLA-matched sibling donors before stem cell collection with recipient-derived clonal myeloma Ig, idiotype (Id), as a tumor antigen, conjugated with keyhole limpet hemocyanin (KLH). Vaccinations were safe in donors and recipients. Donor-derived KLH- and Id-specific humoral and central and effector memory T-cell responses were detectable by day 30 after HSCT and were boosted by post-transplant vaccinations at 3 months in most recipients. One patient died before booster vaccinations. Specifically, after completing treatment, 8/9 myeloma recipients had persistent Id-specific immune responses and 5/9 had improvement in disease status. Although regulatory T cells increased after vaccination, they did not impact immune responses. At a median potential follow-up period of 74 months, 6 patients are alive, the 10 patients have a median PFS of 28.5 months and median OS has not been reached. Our results provide proof of principle that neoantigen and tumor antigen-specific humoral and cellular immunity could be safely induced in HSCT donors and passively transferred to recipients. This general strategy may be used to reduce relapse of malignancies and augment protection against infections after allogeneic HSCT. Bone Marrow Transplantation (2013) 48, 269-277; doi:10.1038/bmt.2012.132; published online 9 July 2012

• 出版日期2013-2
• 单位NIH